semaglutide fda approval history FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to Semaglutide: First Global Approval |
Description
According to its manufacturer, Novo Nordisk, the new incarnation of the prescription drug also helps with chronic weight management in adults with obesity or overweight and is the first daily oral GLP-1 receptor agonist approved for weight loss
Mittlerweile liegen auch erste Ergebnisse aus groen Phase-3-Studien vor
Its interesting to note that semaglutide is part of a broader class of medications, including the newer Mounjaro, that act on the GLP-1 receptor, offering similar benefits as well as potential side effects
Several disease states are associated with dysregulation of parasympathetic outflow to the heart
